论文部分内容阅读
目的:本研究旨在探讨不同化疗方案以及患者年龄对化疗诱导停经的影响,为进一步内分泌治疗药物的选择提供依据。方法:回顾性研究绝经前乳腺癌患者接受化疗后月经变化情况,比较不同化疗方案及患者不同年龄段月经状态变化的差异。结果:在103例患者中,蒽环类与紫杉类化疗组的月经变化差异无统计学意义(P=0.719)。在不同年龄组中,大于45岁患者永久性停经者的比例明显高于45岁以下患者(P<0.001)。低龄患者发生停经要晚于高龄患者(P=0.001)。结论:年龄是化疗诱导停经的重要影响因素,小于45岁的患者月经受化疗影响较小,停经多为可逆性,则内分泌治疗不适宜直接选择芳香化酶抑制剂。紫杉类化疗药物并没有比蒽环类药物对月经影响更大。
Objective: The purpose of this study was to investigate the effects of different chemotherapy regimens and patient age on chemotherapy-induced menopause and to provide evidence for the further selection of endocrine drugs. Methods: The postmenopausal breast cancer patients were retrospectively studied for the changes of menstruation after chemotherapy, and the difference of menstrual status between different chemotherapy regimens and patients was compared. Results: There was no significant difference in menstrual changes between the anthracycline and the taxane chemotherapy group in 103 patients (P = 0.719). In different age groups, the proportion of permanent menopausal patients older than 45 was significantly higher than those under 45 (P <0.001). Older patients with menopause occurred later than in older patients (P = 0.001). Conclusion: Age is an important factor in inducing menopause during chemotherapy. Menstruation in younger than 45 years is less affected by chemotherapy and more menopause is reversible. Endocrine therapy is not suitable for direct selection of aromatase inhibitors. There is no more taxane chemotherapy than anthracycline for menstruation.